free porn
porn
free porn

Agenda

AgendaARM’s Advanced Therapies Investor Day is a full-day meeting comprised of discussions between key opinion leaders, top analysts and senior executives with presentations by the field’s most promising companies.

Program Agenda

7:30am REGISTRATION, BREAKFAST AND NETWORKING
8:00am WELCOME REMARKS
Speaker:
Janet Lynch Lambert, CEO, Alliance for Regenerative Medicine
8:15am FIRESIDE CHAT: IMMUNO-ONCOLOGY
Chair:
Keith Thompson, CEO, Cell and Gene Therapy Catapult
Speaker:
Eric Halioua, President and CEO, PDC*line Pharma
Gregg Sando, Founder and CEO, Cell Medica
8:45am FIRESIDE CHAT: GENE THERAPY
Chair:
Sarah Haecker Meeks, Ph.D., Director, Technology Sections, Alliance for Regenerative Medicine; Chief Scientific Officer, Adjuvant Partners
Speaker:
Rafael Yáñez-Muñoz, Ph.D., Professor of Advanced Therapy, Royal Holloway University of London
9:15am PANEL: HEALTH TECHNOLOGY ASSESSMENT AND ACCESS FOR ATMPs
Chair:
Paolo Morgese, Director, EU Market Access and Member Relations, Alliance for Regenerative Medicine
Speakers:
Eric Faulkner, VP, Precision and Transformative Technology Solutions, Value Demonstration, Access and Commercial, Evidera
Diane Kleinermans, Advisor, Ministry of Public Health and Social Affairs Belgium
Pilar Pinilla-Dominguez, Technical Adviser, National Institute for Health and Care Excellence (NICE)
Holger Raffel, Former Senior Contract Manager, DAK Gesundheit; CEO, HRaffel German Health Consulting
Giovanni Tafuri, Ph.D., Senior HTA Officer, Italian Medicines Agency (AIFA)
10:15am MORNING BREAK
10:30am COMPANY PRESENTATIONS
10:30am Mesoblast
10:45am Orchard Therapeutics
11:00am Kiadis Pharma
11:15am PANEL: ACCELERATED APPROVAL SCHEMES AND THEIR IMPACT ON ATMP PRODUCTS
Chair:
Sven Kili, M.D., VP, Head of Cell and Gene Therapy Development, GlaxoSmithKline (GSK)
Speakers:
Lorcan Allen, Ph.D., Senior Director, EU Regulatory Affairs, BioMarin
Anne Dupraz Poiseau, Ph.D., Chief Regulatory Officer, Orchard Therapeutics
Jordi Llinares Garcia, M.D., Head of Scientific and Regulatory Management, European Medicines Agency (EMA)
Peter Richardson, Ph.D., Head of Quality, European Medicines Agency (EMA)
Chris Sotirelis, Ph.D., Patient Expert, EURORDIS/UK Thalassemia Society
12:15pm LUNCH AND NETWORKING
1:15pm COMPANY PRESENTATIONS
1:15pm ViaCyte
1:30pm PDC*line Pharma
1:45pm ORIG3N
2:00pm Oxford BioMedica
2:15pm TxCell
2:30pm PANEL: ACCESS TO CAPITAL: FINANCING OPPORTUNITIES FOR ATMP COMPANIES
Chair:
Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult
Speakers:
Jasper Bos, Ph.D., VP and Head of Healthcare, Merck Ventures B.V.
Chris Hollowood, Ph.D., Chief Investment Officer and Managing Partner, Syncona
Genghis Lloyd-Harris, M.D., Ph.D., Partner, Abingworth
Paolo Siviero, Senior Advisor and Fund Manager, Principia SGR
3:30pm AFTERNOON BREAK
3:45pm COMPANY PRESENTATIONS
3:45pm Acucela
4:00pm TiGenix
4:15pm ReNeuron
4:30pm Promethera Biosciences
4:45pm CombiGene
5:00pm NETWORKING RECEPTION
6:30pm PROGRAM CLOSE